Here's How Congressman Lost $17M in Single Day

Australian biotech firm's stock drops 90% Tuesday
By Michael Harthorne,  Newser Staff
Posted Jun 27, 2017 5:46 PM CDT
Congressman Loses $17M When Biotech Stock Craters
Rep. Chris Collins of New York, seen here during the Republican National Convention, lost $17 million when an Australian biotech firm's stock cratered Tuesday.   (AP Photo/J. Scott Applewhite)

A Republican congressman from New York lost approximately $17 million Tuesday when the stock value of an Australian biotech firm cratered, Politico reports. It's unclear how much money was lost by his fellow lawmakers, who he convinced to buy into the firm. Rep. Chris Collins is the largest shareholder and sits on the board of Innate Immunotherapeutics. On Tuesday, Innate stock dropped more than 90% after the firm announced its multiple sclerosis drug was a failure in clinical trials. According to CNBC, Innate stock hit a peak of $1.77 per share in January; it closed at 5 cents Tuesday. “For those that invested in Innate including me, we all were sophisticated investors who were aware of the inherent risk," Collins says.

Collins' actual, not-just-on-paper loss is the just over $5 million he invested in Innate about 15 years ago; he hadn't sold any of his Innate stock prior to Tuesday's crash, the Buffalo News reports. The other lawmakers Collins successfully convinced to buy Innate stock are Markwayne Mullin of Oklahoma, Bill Long of Missouri, Mike Conway of Texas, and Doug Lamborn of Colorado. The Office of Congressional Ethics is investigating Collins for possible insider trading. He helped write legislation to speed up clinical trials that could have benefited Innate in theory. Collins, who says he's still "hopeful" Innate can develop a successful MS drug, was worth a reported $40 million prior to Tuesday's stock debacle. (More stocks stories.)

Get the news faster.
Tap to install our app.
Install the Newser News app
in two easy steps:
1. Tap in your navigation bar.
2. Tap to Add to Home Screen.